HuB14-VA-PL2202 / ADC Therapeutics - LARVOL DELTA

HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers (AACR 2025) - "HuB14-VA-PL2202 demonstrated potent and specific in vitro cytotoxicity and in vivo anti-tumor activity in both hematological and solid tumor models, and was well tolerated in cynomolgus monkeys. Together, the data generated with HuB14-VA-PL2202 warrants its further development into the clinic in cancers over-expressing ASCT2."

Acute Myelogenous Leukemia • Colorectal Cancer • Head and Neck Cancer • Hematological Malignancies • Leukemia • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • SLC1A5

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PRNewswire) - "ADC Therapeutics SA...announced abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025....Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models. Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations."

Preclinical • Non Small Cell Lung Cancer • Ovarian Cancer • Prostate Cancer